Frestedt et al. [20] |
325 mg per tablet with 1-2 tablets to be taken every 4–6 hours as needed for pain |
No |
No significant differences between the two groups for rescue medication consumption at any single time point or over time |
No figures given |
|
Karlsson et al. [21] |
≤4000 mg/day could be taken as for unacceptable pain for more than 24 hours |
No |
Rescue medication usage was significantly better than under placebo |
No figures given |
|
Jacquet et al. [22] |
Tablets equivalent to 500 mg paracetamol alone or combined with weak opiates (e.g., coproxamol or coparein) |
Main outcome measure 500 mg paracetamol equivalent tablets per week (PET/week) measured each month |
Single-component Paracetamol (number of users, tablets/week ± SD) Phytalgic 12 (21 ± 14.7) Placebo 15 (15.4 ± 10.4) |
Add-on study to the usual symptomatic medication (analgesics and/or NSAIDs) |
|
Krüger et al. [23] |
500 mg tablets; intake was permitted if necessary due to pain but not 48 hours before visits |
Secondary endpoint, recorded daily by the patient in the diary and checked by the physician at each visit (pill counting) |
Low acetaminophen consumption; differences between the groups not significant |
No figures given |
|
Puopolo et al. [24] |
For breakthrough pain, if needed; no dose reported |
Secondary endpoint; use was determined by tablet counts |
Patients treated with etoricoxib or ibuprofen used significantly less paracetamol than those receiving placebo for breakthrough pain Paracetamol use in the etoricoxib and ibuprofen groups was similar |
Figures not listed in the table of the key secondary results |
|
Reginster et al. [25] |
325 mg tablets; use was restricted (it was not permitted during the initial 2 weeks of treatment) and recorded |
No |
No data shown |
|
|
Sawitzke et al. [26] |
Up to 4 g daily could be taken, but patients were instructed not to take this drug within 24 h of a follow-up visit to allow for accurate measurement of their current pain levels |
No |
The use of paracetamol averaged 570 mg daily. The lowest use was in the celecoxib (465 mg) group and the highest use in the placebo group (645 mg) |
Rank order of rescue drug use (least to greatest) exactly paralleled to that of the primary efficacy outcome |
|
Schnitzer et al. [27] |
500 mg tablets for use in case of increased OA pain, with a maximum accepted dose of 2000 mg/day |
Additional efficacy measures |
Average daily tablets use in the placebo group 1.77 versus 1.33 to 1.43 in the naproxcinod groups and 1.34 in the naproxen group |
|
|
Yang et al. [28] |
Maximum of 4 g/day |
No |
No data shown |
Asked to stop analgesics at least 1 week before completing the questionnaires and visiting their treating orthopaedic surgeon |
|
Thorne et al. [29] |
325 mg to 650 mg every 4 h to 6 h as required |
Secondary end point; compared for each treatment, based on the average daily consumption, and was summarized each week |
Significantly greater use during the placebo phase (3.4 ± 3.6 tablets/day) than during the CR tramadol phase (2.4 ± 3.1 tablets/day) |
|
|